Prescient receives $3.4 million R&D Tax Incentive refund
Prescient Therapeutics (ASX: PTX) has received a cash refund of $3,441,102.65 from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI). The company announced the refund on 12 November 2026.
The refund relates to eligible research and development expenditure incurred in the financial year ended 30 June 2026, principally on the Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company describes it as non-dilutive, and it adds to the $6 million raised in September/October to fund the continued development of PTX-100.
Key facts at a glance:
- Refund amount: $3,441,102.65
- Period covered: financial year ended 30 June 2026
- Main expenditure: Phase 2a study of PTX-100 in relapsed or refractory CTCL
- Earlier funding: $6 million raised in September/October
James McDonnell, CEO
“The R&D Tax Incentive is non-dilutive funding that goes directly into the development of PTX-100. Together with the recent capital raise, it strengthens our position as we approach the first Dose Optimisation Committee review in December.”
When big ASX news breaks, our subscribers know first
What happens next for PTX-100
The first Dose Optimisation Committee review is scheduled for December 2026. 20 evaluable patients (10 in each dosing arm) are now enrolled in the Phase 2 study, which is recruiting globally.
Enrolment continues towards the planned 40 evaluable patients.
PTX-100 holds US FDA Orphan Drug Designation for all T-Cell Lymphomas, and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL.
Clinical oversight of the program also changed hands during the year, with a new Chief Medical Officer appointed from Telix Pharmaceuticals and Roche to guide the global Phase 2 recruitment effort.
Want Alerts Like This on the Biotech Stocks You Follow?
StockWire X Market Intelligence scores every announcement in our coverage for how significant it’s likely to be for investors, and which way it points, then alerts you on the stocks you follow. The first 1,000 founding members lock in 50% off for life: A$247 a year instead of the standard A$495. Join the founding waitlist today.